Potent Anti-Tumor Activity of the AXL-Targeted Antibody-Drug Conjugate, Mipasetamab Uzoptirine (ADCT-601), in Preclinical Models of Adenoid Cystic Carcinoma
- DOI
- 10.1158/1535-7163.mct-25-1323
- Published
- 2026-05-05
- Container
- Molecular Cancer Therapeutics
- Publisher
- American Association for Cancer Research (AACR)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1158/1535-7163.mct-25-1323,
title = {Potent Anti-Tumor Activity of the AXL-Targeted Antibody-Drug Conjugate, Mipasetamab Uzoptirine (ADCT-601), in Preclinical Models of Adenoid Cystic Carcinoma},
author = {Joseph O. Humtsoe and Leilani Jones and Anita Pothukuchi and Karina Chen and Shorook Na’ara and Hyunseok Kang and Patrick K. Ha},
year = {2026},
journal = {Molecular Cancer Therapeutics},
doi = {10.1158/1535-7163.mct-25-1323},
url = {https://doi.org/10.1158/1535-7163.mct-25-1323}
}RIS
TY - JOUR TI - Potent Anti-Tumor Activity of the AXL-Targeted Antibody-Drug Conjugate, Mipasetamab Uzoptirine (ADCT-601), in Preclinical Models of Adenoid Cystic Carcinoma AU - Joseph O. Humtsoe AU - Leilani Jones AU - Anita Pothukuchi AU - Karina Chen AU - Shorook Na’ara AU - Hyunseok Kang AU - Patrick K. Ha PY - 2026 JO - Molecular Cancer Therapeutics DO - 10.1158/1535-7163.mct-25-1323 UR - https://doi.org/10.1158/1535-7163.mct-25-1323 ER -
APA
Humtsoe, J. O., Jones, L., Pothukuchi, A., Chen, K., Na’ara, S., Kang, H., & Ha, P. K. (2026). Potent Anti-Tumor Activity of the AXL-Targeted Antibody-Drug Conjugate, Mipasetamab Uzoptirine (ADCT-601), in Preclinical Models of Adenoid Cystic Carcinoma. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-25-1323
Source records
- crossref · retrieved 2026-11-07T07:07:49.156Z